A30.5

Clinical Causes: Infection with Mycobacterium leprae bacteria Prolonged close contact with untreated individuals with lepromatous leprosy Possible genetic susceptibility affecting immune response

Key Symptoms: Multiple, symmetrical skin lesions including nodules, plaques, and thickened skin Loss of sensation in affected skin areas due to nerve damage Muscle weakness and paralysis in advanced cases Nasal congestion, nosebleeds, or ulceration of nasal tissues Eye problems leading to irritation or vision impairment Widespread tissue destruction in severe cases

Diagnosis Path: Diagnosis typically involves a combination of clinical examination and laboratory tests. Healthcare providers look for characteristic skin lesions and nerve involvement. Confirmatory tests include skin smears for acid-fast bacilli and skin biopsies, which reveal the presence of Mycobacterium leprae. Additional tests might include nerve conduction studies to assess nerve damage and imaging as necessary.

Treatment Protocols: Treatment for lepromatous leprosy involves multidrug therapy (MDT), which combines antibiotics such as dapsone, rifampicin, and clofazimine. The duration of treatment usually extends over 12 months or longer, depending on the response. Early diagnosis and consistent adherence to therapy are vital to prevent disabling complications and reduce transmission. Supportive care may include wound management, physical therapy, and eye care to address specific symptoms.